You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk
  1. Anil Pareek1,
  2. Indranil Purkait2,
  3. Ravi T Mehta2,
  4. Anu Grover2
  1. 1 Medical Affairs and Clinical Research, Ipca Laboratories Ltd., Mumbai, Maharashtra, India
  2. 2 Medical Affairs, Ipca Laboratories Ltd., Mumbai, Maharashtra, India
  1. Correspondence to Dr Anil Pareek, Medical Affairs and Clinical Research , Ipca Laboratories Ltd, Mumbai-400067, Maharashtra, India; anil.pareek{at}ipca.com

https://doi.org/10.1136/annrheumdis-2017-212499

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We complement the authors on their systematic review and meta-analysis on metabolic and cardiovascular (CV) benefits of hydroxychloroquine (HCQ).1 The authors have restricted the meta-analysis to studies comparing HCQ users versus non-users in rheumatoid arthritis (RA). This criterion has precluded the inclusion of many studies where metabolic and CV benefits of HCQ have been reported. We would like to highlight these to add to the significant benefits of this molecule, thus widening the evidence base.

    Authors did not include studies comparing HCQ with other disease-modifying antirheumatic drugs (DMARDs) and biologicals. In a study cohort of 13 905 participants, majority of …

    View Full Text

    Footnotes

    • Competing interests Authors are involved in research studies on hydroxychloroquine.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles